List of bibliographic references
Number of relevant bibliographic references: 2.
List of associated KwdEn.i
Nombre de documents | Descripteur |
2 | Adalimumab |
2 | Monoclonal antibody |
2 | Rheumatoid arthritis |
2 | Rheumatology |
1 | ACR, American College of Rheumatology |
1 | ANA, antinuclear antibody |
1 | Abbott laboratories |
1 | Adalimumab monotherapy |
1 | Adalimumab treatment groups |
1 | Adverse event |
1 | Adverse events |
1 | American college |
1 | Antirheumatic drugs |
1 | Arthritis |
1 | Arthritis rheum |
1 | Atkins |
1 | Baseline |
1 | Baseline value |
1 | CRP, C reactive protein |
1 | Chronic |
1 | Concomitant |
1 | Concomitant methotrexate |
1 | DAS, disease activity score |
1 | DMARDs, disease modifying antirheumatic drugs |
1 | Disability index |
1 | Disease activity |
1 | Disease activity score |
1 | Dmard |
1 | Dmards |
1 | Dos |
1 | Drug |
1 | ESR, erythrocyte sedimentation rate |
1 | EULAR, European League Against Rheumatism |
1 | Erythrocyte sedimentation rate |
1 | Eular |
1 | Eular response |
1 | Eular response rates |
1 | European league |
1 | Good eular response |
1 | HAQ DI, Disability Index of the Health Assessment Questionnaire |
1 | Health assessment questionnaire |
1 | Human |
1 | Injection site reaction |
1 | MTX, methotrexate |
1 | Methotrexate |
1 | Monoclonal |
1 | Monotherapy |
1 | NSAIDs, non-steroidal anti-inflammatory drugs |
1 | Other week |
1 | Patient assessment |
1 | Percentage change |
1 | Placebo |
1 | Previous dmard treatment |
1 | Primary efficacy |
1 | Putte |
1 | RA, rheumatoid arthritis |
1 | Randomised |
1 | Reactive protein |
1 | Regimen |
1 | Respective adalimumab doses |
1 | Response criteria |
1 | Response rates |
1 | Rheum |
1 | Rheumatoid |
1 | Riel |
1 | Riel plcm |
1 | Safety |
1 | Sample size |
1 | Serious infections |
1 | Significant difference |
1 | Significant differences |
1 | Study drug |
1 | TNF, tumour necrosis factor |
1 | Toxicity |
1 | Traditional dmards |
1 | Treatment |
1 | Treatment group |
1 | Treatment groups |
1 | Tumour necrosis factor |
1 | adalimumab |
1 | disease modifying antirheumatic drugs |
1 | human monoclonal antibodies |
1 | monotherapy |
1 | rheumatoid arthritis |
1 | tumour necrosis factor α |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "H. Kupper"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "H. Kupper" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= H. Kupper
}}
| This area was generated with Dilib version V0.6.33. Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 | ![](Common/icons/LogoDilib.gif) |